2020
Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer
Licata L, Viale G, Criscitiello C, Giordano A, Chavez-MacGregor M, Curigliano G, Foldi J, Oke O, Giuliano M, Collins R, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Gerratana L, Giordano S, Rognone A, Sica L, Pusztai L, Bianchini G. Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer. Annals Of Oncology 2020, 31: s317-s318. DOI: 10.1016/j.annonc.2020.08.309.Peer-Reviewed Original Research
2015
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
Thaker NG, Hoffman KE, Stauder MC, Shaitelman SF, Strom EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. SpringerPlus 2015, 4: 36. PMID: 25674496, PMCID: PMC4318826, DOI: 10.1186/s40064-015-0840-y.Peer-Reviewed Original ResearchIpsilateral breast tumor recurrenceRecurrence scoreBreast cancerRisk of IBTRGrade I/II diseaseLymph node-negative breast cancerNode-negative breast cancerStage I/IIRisk of LRBreast tumor recurrenceLocoregional recurrence riskKi-67 expressionIndividualized treatment decisionsLow event ratesIBTR rateMost patientsConsecutive patientsMedian ageRS testingProspective studyRetrospective studyTumor recurrenceTreatment decisionsRadiation therapyRecurrence risk
2012
Adjuvant therapy in stage I carcinoma of the breast
Schwartz GF, Reis‐Fihlo J, Pusztai L, Fentiman IS, Holland R, Bartelink H, Rutgers EJ, Solin LJ, Palazzo J, Committee A. Adjuvant therapy in stage I carcinoma of the breast. Cancer 2012, 118: 2031-2038. PMID: 22392361, DOI: 10.1002/cncr.27431.Peer-Reviewed Original ResearchConceptsStage I breast cancerI breast cancerBreast cancerAdjuvant therapyConsensus conferenceStage ILymph node-negative breast cancerNode-negative breast cancerKimmel Cancer CenterAdjuvant chemotherapyAdjuvant hormonesAdjuvant treatmentCancer CenterClinical trialsThomas Jefferson UniversityTreatment criteriaTreatment decisionsIndividual tumorsCancerGenetic factorsChemotherapyMolecular phenotypingTherapyHormoneCurrent data
2011
Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF, Pusztai L, Brunak S, Richardson AL, Szallasi Z. Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. BMC Bioinformatics 2011, 12: 310. PMID: 21798043, PMCID: PMC3155975, DOI: 10.1186/1471-2105-12-310.Peer-Reviewed Original ResearchConceptsEarly-stage lung cancerStage lung cancerNegative breast cancerCancer treatment decisionsHuman tumor samplesNeoadjuvant therapyChemotherapy responseLung cancerBreast cancerTreatment decisionsIndependent cohortPrognostic classifierAccurate biomarkersCancer expression profilesTumor typesPotential biomarkersTumor samplesConclusionsThese resultsSpecific predictorsStrong associationReliable predictorCohortCancerPredictorsBiomarkers